Preclinical studies have shown that GITR agonistic agents (like DTA-1) can mediate tumor regression in animal models in part based on a unique mechanism causing Tregs to lose lineage stability, reducing their suppressive influence over the tumor microenvironment [68]. The gene discussed is TNFRSF18; the disease is neoplasm.